Free Trial

Cross Country Healthcare (CCRN) Financials

Cross Country Healthcare logo
$13.62 +0.09 (+0.67%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Cross Country Healthcare

Annual Income Statements for Cross Country Healthcare

This table shows Cross Country Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-15 73 186
Consolidated Net Income / (Loss)
-15 73 186
Net Income / (Loss) Continuing Operations
-15 73 186
Total Pre-Tax Income
-16 103 253
Total Operating Income
-17 113 270
Total Gross Profit
1,323 2,005 2,794
Total Revenue
1,344 2,020 2,803
Operating Revenue
1,344 2,020 2,803
Total Cost of Revenue
21 15 9.61
Other Cost of Revenue
21 15 9.61
Total Operating Expenses
1,339 1,892 2,524
Selling, General & Admin Expense
233 300 324
Depreciation Expense
18 18 13
Other Operating Expenses / (Income)
1,076 1,570 2,180
Impairment Charge
2.89 0.72 5.60
Restructuring Charge
8.55 2.61 1.86
Total Other Income / (Expense), net
0.47 -9.90 -17
Interest Expense
2.19 9.82 18
Interest & Investment Income
2.05 0.00 0.00
Other Income / (Expense), net
0.61 -0.09 1.33
Income Tax Expense
-1.84 30 67
Basic Earnings per Share
($0.44) $2.07 $5.02
Weighted Average Basic Shares Outstanding
33.38M 35.16M 37.01M
Diluted Earnings per Share
($0.44) $2.05 $4.95
Weighted Average Diluted Shares Outstanding
33.38M 35.48M 37.54M
Weighted Average Basic & Diluted Shares Outstanding
32.81M 34.73M 36.82M

Quarterly Income Statements for Cross Country Healthcare

This table shows Cross Country Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-3.75 2.56 -16 2.69 9.04 13 21 29 36 35
Consolidated Net Income / (Loss)
-3.75 2.56 -16 2.69 9.04 13 21 29 36 35
Net Income / (Loss) Continuing Operations
-3.75 2.56 -16 2.69 9.04 13 21 29 36 35
Total Pre-Tax Income
-3.91 3.39 -20 3.69 13 20 30 40 43 49
Total Operating Income
-3.43 2.85 -19 2.92 13 20 35 44 48 52
Total Gross Profit
310 314 321 378 410 440 538 618 1,202 635
Total Revenue
310 315 340 379 414 442 541 623 625 636
Operating Revenue
310 315 340 379 414 442 541 623 625 636
Total Cost of Revenue
-0.23 1.51 19 1.29 4.17 2.36 3.13 4.91 -577 1.10
Other Cost of Revenue
-0.23 1.51 19 1.29 4.17 2.36 3.13 4.91 - 1.10
Total Operating Expenses
314 311 340 375 396 420 502 574 1,154 583
Selling, General & Admin Expense
56 54 60 63 68 70 79 84 81 81
Depreciation Expense
4.34 4.50 4.72 4.64 4.47 4.54 4.43 4.90 3.16 3.21
Other Operating Expenses / (Income)
247 251 273 306 324 345 418 484 1,070 493
Impairment Charge
2.17 0.00 0.11 0.60 - 0.19 0.53 0.00 - 3.86
Restructuring Charge
4.50 1.00 2.12 0.94 0.92 0.35 0.91 0.43 0.00 2.49
Total Other Income / (Expense), net
-0.48 0.54 -0.36 0.77 -0.54 -0.80 -4.88 -3.68 -5.12 -3.47
Interest Expense
0.61 0.55 0.57 0.46 0.59 0.67 4.87 3.69 5.33 3.50
Other Income / (Expense), net
-0.82 -0.02 0.21 1.23 0.05 -0.14 -0.01 0.01 0.21 0.03
Income Tax Expense
-0.16 0.83 -3.51 1.00 3.93 6.69 8.96 11 6.81 14
Basic Earnings per Share
($0.13) $0.08 ($0.47) $0.08 $0.28 $0.37 $0.60 $0.82 $1.00 $0.94
Weighted Average Basic Shares Outstanding
33.38M 33.02M 33.96M 34.22M 35.16M 34.95M 35.35M 35.86M 37.01M 37.10M
Diluted Earnings per Share
($0.13) $0.08 ($0.47) $0.08 $0.28 $0.36 $0.60 $0.81 $0.99 $0.93
Weighted Average Diluted Shares Outstanding
33.38M 33.06M 33.96M 34.60M 35.48M 35.15M 35.52M 36.56M 37.54M 37.49M
Weighted Average Basic & Diluted Shares Outstanding
32.81M 32.92M 33.81M 34.77M 34.73M 35.15M 35.80M 35.93M 36.82M 37.30M

Annual Cash Flow Statements for Cross Country Healthcare

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
65 13 2.57
Net Cash From Operating Activities
120 248 134
Net Cash From Continuing Operating Activities
120 248 134
Net Income / (Loss) Continuing Operations
-15 73 186
Consolidated Net Income / (Loss)
-15 73 186
Depreciation Expense
18 18 13
Non-Cash Adjustments To Reconcile Net Income
28 24 29
Changes in Operating Assets and Liabilities, net
88 133 -94
Net Cash From Investing Activities
-8.71 -14 -44
Net Cash From Continuing Investing Activities
-8.71 -14 -44
Purchase of Property, Plant & Equipment
-8.71 -14 -8.79
Acquisitions
0.00 0.00 -35
Other Investing Activities, net
0.00 0.20 0.09
Net Cash From Financing Activities
-47 -221 -88
Net Cash From Continuing Financing Activities
-47 -221 -88
Repayment of Debt
-18 -872 -1,740
Repurchase of Common Equity
-37 -58 -35
Issuance of Debt
18 721 1,700
Other Financing Activities, net
-9.54 -12 -13
Other Net Changes in Cash
-0.01 0.01 -0.01
Cash Interest Paid
1.37 7.53 13
Cash Income Taxes Paid
2.43 22 83

Quarterly Cash Flow Statements for Cross Country Healthcare

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
18 -5.58 64 -12 2.79 14 0.38 -3.31 -27 30
Net Cash From Operating Activities
24 7.47 82 6.01 12 70 119 47 4.32 141
Net Cash From Continuing Operating Activities
24 7.47 82 6.01 12 70 119 47 4.32 141
Net Income / (Loss) Continuing Operations
-3.75 2.56 -16 2.69 9.04 13 21 29 36 35
Consolidated Net Income / (Loss)
-3.75 2.56 -16 2.69 9.04 13 21 29 36 35
Depreciation Expense
4.34 4.50 4.72 4.64 4.47 4.54 4.43 4.90 3.16 3.21
Non-Cash Adjustments To Reconcile Net Income
2.34 0.53 22 3.42 1.15 5.98 9.81 7.43 4.90 8.95
Changes in Operating Assets and Liabilities, net
21 -0.11 72 -4.74 -2.58 47 84 5.10 -40 94
Net Cash From Investing Activities
-2.53 -1.12 -2.85 -2.21 -2.88 -3.41 -4.00 -3.50 -37 -2.92
Net Cash From Continuing Investing Activities
-2.53 -1.12 -2.85 -2.21 -2.88 -3.41 -4.00 -3.50 -37 -2.92
Purchase of Property, Plant & Equipment
-2.53 -1.12 -2.85 -2.21 -2.88 -3.43 -4.00 -3.68 -2.02 -2.92
Net Cash From Financing Activities
-4.08 -12 -15 -16 -6.42 -53 -115 -47 6.08 -108
Net Cash From Continuing Financing Activities
-4.08 -12 -15 -16 -6.42 -53 -115 -47 6.08 -108
Repayment of Debt
-0.35 -0.35 -3.15 -14 -56 -143 -316 -358 -407 -452
Repurchase of Common Equity
-4.08 -12 -15 -6.37 -6.40 -15 -4.72 -32 -11 -24
Issuance of Debt
0.35 0.35 3.15 14 56 112 206 347 424 376
Other Net Changes in Cash
-0.01 - - - - - - -0.00 - -

Annual Balance Sheets for Cross Country Healthcare

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
589 681 950
Total Current Assets
335 417 677
Cash & Equivalents
82 17 3.60
Accounts Receivable
223 372 642
Prepaid Expenses
7.85 7.68 11
Current Deferred & Refundable Income Taxes
10 8.62 13
Other Current Assets
12 11 8.48
Plant, Property, & Equipment, net
29 27 20
Total Noncurrent Assets
225 237 253
Noncurrent Note & Lease Receivables
21 26 23
Goodwill
135 135 163
Intangible Assets
42 54 45
Noncurrent Deferred & Refundable Income Taxes
8.10 5.98 7.12
Other Noncurrent Operating Assets
19 15 14
Total Liabilities & Shareholders' Equity
589 681 950
Total Liabilities
170 213 498
Total Current Liabilities
120 156 279
Short-Term Debt
4.41 6.79 7.50
Accounts Payable
65 93 193
Current Employee Benefit Liabilities
48 52 73
Other Current Liabilities
3.40 4.16 6.03
Total Noncurrent Liabilities
50 57 70
Noncurrent Deferred & Payable Income Tax Liabilities
10 11 7.65
Other Noncurrent Operating Liabilities
40 47 63
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
419 468 451
Total Preferred & Common Equity
419 468 451
Total Common Equity
419 468 451
Common Stock
202 236 293
Retained Earnings
218 233 160
Accumulated Other Comprehensive Income / (Loss)
-1.44 -1.39 -1.39

Quarterly Balance Sheets for Cross Country Healthcare

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
597 603 648 708 771 921 883
Total Current Assets
337 338 387 445 506 649 660
Cash & Equivalents
64 70 5.24 14 0.67 0.29 30
Accounts Receivable
245 242 357 410 485 627 611
Prepaid Expenses
4.55 6.25 7.62 4.78 6.75 11 3.95
Current Deferred & Refundable Income Taxes
10 8.97 6.33 5.24 4.13 1.78 -
Other Current Assets
13 11 11 11 9.20 8.53 15
Plant, Property, & Equipment, net
29 29 28 26 25 23 19
Total Noncurrent Assets
232 236 233 236 241 249 204
Noncurrent Note & Lease Receivables
22 23 23 22 22 23 21
Goodwill
135 135 135 135 137 142 113
Intangible Assets
46 49 52 57 60 63 47
Noncurrent Deferred & Refundable Income Taxes
9.04 10 6.81 6.53 7.62 7.71 8.79
Other Noncurrent Operating Assets
19 18 16 15 14 14 14
Total Liabilities & Shareholders' Equity
597 603 648 708 771 921 883
Total Liabilities
173 164 180 238 301 469 460
Total Current Liabilities
121 110 128 184 216 265 277
Short-Term Debt
4.10 4.10 4.10 6.91 16 13 7.50
Accounts Payable
58 56 69 115 140 177 192
Current Employee Benefit Liabilities
54 47 52 57 56 70 71
Other Current Liabilities
3.86 3.72 3.82 4.45 4.65 5.84 6.29
Total Noncurrent Liabilities
52 54 52 55 85 204 183
Capital Lease Obligations
2.35 - - - - - -
Noncurrent Deferred & Payable Income Tax Liabilities
11 12 11 9.91 9.19 8.43 0.24
Other Noncurrent Operating Liabilities
39 42 40 45 45 57 53
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
425 439 468 470 470 452 423
Total Preferred & Common Equity
425 439 468 470 470 452 423
Total Common Equity
425 439 468 470 470 452 423
Common Stock
204 215 229 242 255 258 297
Retained Earnings
222 225 241 229 217 195 127
Accumulated Other Comprehensive Income / (Loss)
-1.40 -1.39 -1.39 -1.39 -1.38 -1.38 -1.37

Annual Metrics And Ratios for Cross Country Healthcare

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
-33.46% -27.95% 67.20%
EBITDA Growth
-98.52% -53.85% 89.28%
EBIT Growth
-114.44% -58.47% 93.62%
NOPAT Growth
-114.84% -59.88% 43.66%
Net Income Growth
-120.04% -60.95% 40.89%
EPS Growth
-121.46% -58.59% 40.23%
Operating Cash Flow Growth
-51.66% 85.38% 256.57%
Free Cash Flow Firm Growth
-54.13% 187.42% 157.33%
Invested Capital Growth
-25.28% -24.29% 24.68%
Revenue Q/Q Growth
-7.19% -9.59% -0.56%
EBITDA Q/Q Growth
-90.24% -21.98% -8.76%
EBIT Q/Q Growth
-1,149.71% -25.33% -9.26%
NOPAT Q/Q Growth
-40,650.06% -29.75% -16.93%
Net Income Q/Q Growth
-724.70% -29.06% -18.16%
EPS Q/Q Growth
-1,366.67% -27.56% -17.91%
Operating Cash Flow Q/Q Growth
11.26% 3.22% 137.82%
Free Cash Flow Firm Q/Q Growth
9.06% 25.29% 127.28%
Invested Capital Q/Q Growth
-6.91% -1.06% 14.06%
Profitability Metrics
- - -
Gross Margin
98.41% 99.28% 99.66%
EBITDA Margin
0.14% 6.48% 10.12%
Operating Margin
-1.25% 5.58% 9.63%
EBIT Margin
-1.21% 5.58% 9.67%
Profit (Net Income) Margin
-1.08% 3.60% 6.63%
Tax Burden Percent
88.77% 70.59% 73.48%
Interest Burden Percent
100.85% 91.36% 93.32%
Effective Tax Rate
0.00% 29.41% 26.52%
Return on Invested Capital (ROIC)
-2.95% 14.99% 36.43%
ROIC Less NNEP Spread (ROIC-NNEP)
3.33% 5.25% 29.17%
Return on Net Nonoperating Assets (RNNOA)
-0.33% 0.81% 13.23%
Return on Equity (ROE)
-3.28% 15.80% 49.66%
Cash Return on Invested Capital (CROIC)
25.98% 42.64% 14.47%
Operating Return on Assets (OROA)
-2.56% 13.81% 32.24%
Return on Assets (ROA)
-2.29% 8.91% 22.11%
Return on Common Equity (ROCE)
-3.28% 15.80% 49.66%
Return on Equity Simple (ROE_SIMPLE)
-3.47% 15.53% 41.19%
Net Operating Profit after Tax (NOPAT)
-12 80 198
NOPAT Margin
-0.88% 3.94% 7.07%
Net Nonoperating Expense Percent (NNEP)
-6.29% 9.74% 7.26%
Return On Investment Capital (ROIC_SIMPLE)
-2.79% 16.77% 43.21%
Cost of Revenue to Revenue
1.59% 0.72% 0.34%
SG&A Expenses to Revenue
17.36% 14.87% 11.56%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
99.66% 93.70% 90.03%
Earnings before Interest and Taxes (EBIT)
-16 113 271
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1.94 131 284
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.43 1.70 2.19
Price to Tangible Book Value (P/TBV)
2.47 2.87 4.07
Price to Revenue (P/Rev)
0.44 0.39 0.35
Price to Earnings (P/E)
0.00 10.96 5.33
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 9.13% 18.77%
Enterprise Value to Invested Capital (EV/IC)
1.52 1.72 1.65
Enterprise Value to Revenue (EV/Rev)
0.39 0.39 0.35
Enterprise Value to EBITDA (EV/EBITDA)
268.32 6.00 3.51
Enterprise Value to EBIT (EV/EBIT)
0.00 6.97 3.67
Enterprise Value to NOPAT (EV/NOPAT)
0.00 9.87 5.02
Enterprise Value to Operating Cash Flow (EV/OCF)
4.33 3.16 7.42
Enterprise Value to Free Cash Flow (EV/FCFF)
5.01 3.47 12.63
Leverage & Solvency
- - -
Debt to Equity
0.01 0.01 0.02
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.10 0.15 0.45
Leverage Ratio
1.43 1.77 2.25
Compound Leverage Factor
1.44 1.62 2.10
Debt to Total Capital
1.04% 1.43% 1.63%
Short-Term Debt to Total Capital
1.04% 1.43% 1.63%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
98.96% 98.57% 98.37%
Debt to EBITDA
2.27 0.05 0.03
Net Debt to EBITDA
-39.81 -0.08 0.01
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
-0.37 0.09 0.04
Net Debt to NOPAT
6.54 -0.13 0.02
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
5.25 6.69 5.83
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
2.78 2.67 2.43
Quick Ratio
2.53 2.50 2.31
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
104 226 79
Operating Cash Flow to CapEx
1,378.43% 1,778.29% 1,525.72%
Free Cash Flow to Firm to Interest Expense
47.44 23.05 4.35
Operating Cash Flow to Interest Expense
54.90 25.31 7.40
Operating Cash Flow Less CapEx to Interest Expense
50.92 23.89 6.91
Efficiency Ratios
- - -
Asset Turnover
2.12 2.48 3.33
Accounts Receivable Turnover
4.51 3.98 4.94
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
47.84 85.94 157.96
Accounts Payable Turnover
0.27 0.10 0.06
Days Sales Outstanding (DSO)
80.87 91.62 73.92
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
1,343.44 3,582.05 5,749.99
Cash Conversion Cycle (CCC)
-1,262.57 -3,490.43 -5,676.07
Capital & Investment Metrics
- - -
Invested Capital
342 457 604
Invested Capital Turnover
3.36 3.81 5.15
Increase / (Decrease) in Invested Capital
-116 -147 120
Enterprise Value (EV)
521 786 995
Market Capitalization
598 796 991
Book Value per Share
$12.73 $13.30 $12.11
Tangible Book Value per Share
$7.34 $7.90 $6.53
Total Capital
423 474 459
Total Debt
4.41 6.79 7.50
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-77 -10 3.90
Capital Expenditures (CapEx)
8.71 14 8.79
Debt-free, Cash-free Net Working Capital (DFCFNWC)
137 250 402
Debt-free Net Working Capital (DFNWC)
219 268 406
Net Working Capital (NWC)
215 261 398
Net Nonoperating Expense (NNE)
2.75 6.93 12
Net Nonoperating Obligations (NNO)
-77 -10 153
Total Depreciation and Amortization (D&A)
18 18 13
Debt-free, Cash-free Net Working Capital to Revenue
10.22% 12.40% 14.35%
Debt-free Net Working Capital to Revenue
16.30% 13.25% 14.47%
Net Working Capital to Revenue
15.97% 12.91% 14.21%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($0.44) $2.07 $5.09
Adjusted Weighted Average Basic Shares Outstanding
33.38M 35.16M 37.01M
Adjusted Diluted Earnings per Share
($0.44) $2.05 $5.02
Adjusted Weighted Average Diluted Shares Outstanding
33.38M 35.48M 37.54M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
32.81M 34.73M 36.82M
Normalized Net Operating Profit after Tax (NOPAT)
-3.80 82 204
Normalized NOPAT Margin
-0.28% 4.06% 7.27%
Pre Tax Income Margin
-1.22% 5.09% 9.03%
Debt Service Ratios
- - -
EBIT to Interest Expense
-7.43 11.47 14.97
NOPAT to Interest Expense
-5.40 8.10 10.95
EBIT Less CapEx to Interest Expense
-11.41 10.05 14.48
NOPAT Less CapEx to Interest Expense
-9.38 6.68 10.46
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
-256.32% 79.38% 18.97%

Quarterly Metrics And Ratios for Cross Country Healthcare

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
-25.14% -28.75% -37.16% -39.11% -33.75% -30.47% -28.25% -21.05% -2.45% 69.67%
EBITDA Growth
-99.49% -70.33% -136.04% -81.95% -65.22% -55.42% -52.51% -47.82% -34.54% 87.84%
EBIT Growth
-131.53% -85.96% -153.99% -90.52% -72.18% -61.37% -55.98% -51.67% -36.36% 94.62%
NOPAT Growth
-125.69% -83.88% -154.25% -93.37% -76.97% -64.21% -55.93% -50.17% -49.47% 48.19%
Net Income Growth
-141.52% -80.06% -175.19% -90.85% -75.11% -63.18% -59.65% -52.51% -53.19% 48.48%
EPS Growth
-146.43% -77.78% -178.33% -90.12% -71.72% -61.29% -57.14% -50.31% -52.17% 50.00%
Operating Cash Flow Growth
100.71% -89.38% -30.90% -87.17% 179.49% -50.00% 557.34% 261.39% 105.89% 5,067.40%
Free Cash Flow Firm Growth
-27.48% 20.55% -1.71% 967.79% 297.72% 148.38% 147.22% 104.91% 59.51% -68.71%
Invested Capital Growth
-25.28% -20.58% -27.67% -22.49% -24.29% -12.72% -17.15% 3.30% 24.68% 62.69%
Revenue Q/Q Growth
-1.64% -7.26% -10.39% -8.42% -6.39% -18.20% -13.17% -0.88% -1.75% -15.59%
EBITDA Q/Q Growth
-98.74% 151.35% -262.35% -51.22% -27.35% -37.63% -18.69% -11.18% -6.88% -33.56%
EBIT Q/Q Growth
-250.04% 114.91% -557.58% -69.38% -33.16% -42.68% -19.70% -15.23% -7.20% -34.68%
NOPAT Q/Q Growth
-211.73% 116.00% -730.72% -77.21% -29.87% -46.18% -22.87% -25.39% 8.98% -33.72%
Net Income Q/Q Growth
-246.89% 115.92% -696.21% -70.21% -29.46% -39.98% -27.49% -24.12% 4.37% -34.22%
EPS Q/Q Growth
-262.50% 117.02% -687.50% -71.43% -22.22% -40.00% -25.93% -23.58% 6.45% -33.57%
Operating Cash Flow Q/Q Growth
224.42% -90.93% 1,270.84% -50.22% -82.83% -41.04% 154.45% 984.84% -96.93% 675.19%
Free Cash Flow Firm Q/Q Growth
16.35% -24.85% -5.95% -11.82% 93.41% -38.72% 921.65% 115.68% 52.67% 40.20%
Invested Capital Q/Q Growth
-6.91% -1.72% -20.02% 0.85% -1.06% -10.50% -14.29% -1.19% 14.06% -15.04%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.07% 99.52% 94.45% 99.66% 98.99% 99.47% 99.42% 99.21% 192.32% 99.83%
EBITDA Margin
0.03% 2.33% -4.20% 2.32% 4.33% 5.59% 7.33% 7.82% 8.26% 8.71%
Operating Margin
-1.11% 0.91% -5.65% 0.77% 3.24% 4.59% 6.51% 7.03% 7.72% 8.20%
EBIT Margin
-1.37% 0.90% -5.59% 1.09% 3.26% 4.56% 6.51% 7.04% 7.75% 8.21%
Profit (Net Income) Margin
-1.21% 0.81% -4.72% 0.71% 2.18% 2.90% 3.95% 4.73% 5.81% 5.47%
Tax Burden Percent
95.89% 75.39% 82.05% 72.97% 69.69% 65.70% 70.43% 73.37% 84.21% 71.44%
Interest Burden Percent
92.12% 119.67% 102.99% 88.87% 96.23% 96.71% 86.15% 91.58% 89.02% 93.30%
Effective Tax Rate
0.00% 24.61% 0.00% 27.03% 30.31% 34.30% 29.57% 26.63% 15.79% 28.56%
Return on Invested Capital (ROIC)
-2.61% 2.38% -14.01% 1.87% 8.60% 13.58% 19.53% 22.98% 33.47% 38.63%
ROIC Less NNEP Spread (ROIC-NNEP)
0.48% 1.14% 12.89% 2.62% 8.15% 12.52% 16.87% 21.55% 30.94% 36.33%
Return on Net Nonoperating Assets (RNNOA)
-0.05% -0.08% -0.27% 0.43% 1.26% 1.40% 4.95% 10.08% 14.03% 12.25%
Return on Equity (ROE)
-2.66% 2.30% -14.28% 2.29% 9.86% 14.98% 24.48% 33.06% 47.50% 50.88%
Cash Return on Invested Capital (CROIC)
25.98% 22.95% 34.12% 34.62% 42.64% 36.42% 42.84% 25.18% 14.47% 8.10%
Operating Return on Assets (OROA)
-2.90% 1.99% -12.82% 2.48% 8.06% 12.81% 18.47% 20.23% 25.83% 32.98%
Return on Assets (ROA)
-2.56% 1.80% -10.83% 1.61% 5.41% 8.14% 11.21% 13.59% 19.36% 21.98%
Return on Common Equity (ROCE)
-2.66% 2.30% -14.28% 2.29% 9.86% 14.98% 24.48% 33.06% 47.50% 50.88%
Return on Equity Simple (ROE_SIMPLE)
0.00% -0.42% 1.93% 9.80% 0.00% 21.80% 26.44% 34.50% 0.00% 53.76%
Net Operating Profit after Tax (NOPAT)
-2.40 2.15 -13 2.13 9.36 13 25 32 41 37
NOPAT Margin
-0.78% 0.68% -3.96% 0.56% 2.26% 3.02% 4.58% 5.16% 6.50% 5.86%
Net Nonoperating Expense Percent (NNEP)
-3.08% 1.24% -26.90% -0.75% 0.45% 1.06% 2.66% 1.43% 2.54% 2.30%
Return On Investment Capital (ROIC_SIMPLE)
-0.57% - - - 1.97% - - - 8.85% -
Cost of Revenue to Revenue
-0.07% 0.48% 5.55% 0.34% 1.01% 0.53% 0.58% 0.79% -92.32% 0.17%
SG&A Expenses to Revenue
17.93% 17.23% 17.73% 16.68% 16.30% 15.74% 14.60% 13.53% 12.90% 12.69%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
101.18% 98.61% 100.10% 98.89% 95.75% 94.88% 92.91% 92.18% 184.61% 91.62%
Earnings before Interest and Taxes (EBIT)
-4.25 2.83 -19 4.15 13 20 35 44 48 52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
0.09 7.33 -14 8.79 18 25 40 49 52 55
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.43 1.07 1.10 1.41 1.70 1.89 2.15 1.82 2.19 2.57
Price to Tangible Book Value (P/TBV)
2.47 1.87 1.89 2.34 2.87 3.20 3.69 3.32 4.07 4.13
Price to Revenue (P/Rev)
0.44 0.31 0.31 0.37 0.39 0.40 0.42 0.31 0.35 0.38
Price to Earnings (P/E)
0.00 0.00 56.67 14.34 10.96 8.67 8.11 5.27 5.33 4.77
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 1.76% 6.97% 9.13% 11.54% 12.33% 18.97% 18.77% 20.95%
Enterprise Value to Invested Capital (EV/IC)
1.52 1.08 1.11 1.41 1.72 1.90 2.04 1.61 1.65 2.25
Enterprise Value to Revenue (EV/Rev)
0.39 0.27 0.26 0.37 0.39 0.39 0.43 0.37 0.35 0.42
Enterprise Value to EBITDA (EV/EBITDA)
268.32 19.96 11.16 7.21 6.00 5.24 5.31 4.01 3.51 3.83
Enterprise Value to EBIT (EV/EBIT)
0.00 256.17 22.02 8.99 6.97 5.84 5.77 4.27 3.67 3.99
Enterprise Value to NOPAT (EV/NOPAT)
0.00 13,629.97 46.59 13.24 9.87 7.77 7.69 5.77 5.02 4.99
Enterprise Value to Operating Cash Flow (EV/OCF)
4.33 3.68 2.43 3.16 3.16 3.66 3.39 4.63 7.42 21.14
Enterprise Value to Free Cash Flow (EV/FCFF)
5.01 4.17 2.74 3.55 3.47 4.87 4.32 6.51 12.63 34.39
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.01 0.02 0.01 0.01 0.01 0.01 0.10 0.33 0.02 0.32
Long-Term Debt to Equity
0.00 0.01 0.00 0.00 0.00 0.00 0.07 0.31 0.00 0.31
Financial Leverage
-0.10 -0.07 -0.02 0.16 0.15 0.11 0.29 0.47 0.45 0.34
Leverage Ratio
1.43 1.46 1.51 1.71 1.77 1.78 1.94 2.27 2.25 2.19
Compound Leverage Factor
1.32 1.75 1.56 1.52 1.71 1.72 1.67 2.08 2.00 2.05
Debt to Total Capital
1.04% 1.50% 0.93% 0.87% 1.43% 1.45% 9.05% 25.04% 1.63% 24.51%
Short-Term Debt to Total Capital
1.04% 0.95% 0.93% 0.87% 1.43% 1.45% 3.06% 2.07% 1.63% 1.34%
Long-Term Debt to Total Capital
0.00% 0.54% 0.00% 0.00% 0.00% 0.00% 5.99% 22.96% 0.00% 23.17%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
98.96% 98.50% 99.07% 99.13% 98.57% 98.55% 90.95% 74.96% 98.37% 75.49%
Debt to EBITDA
2.27 0.32 0.11 0.05 0.05 0.04 0.24 0.62 0.03 0.44
Net Debt to EBITDA
-39.81 -2.90 -1.76 -0.01 -0.08 -0.04 0.23 0.62 0.01 0.34
Long-Term Debt to EBITDA
0.00 0.12 0.00 0.00 0.00 0.00 0.16 0.57 0.00 0.42
Debt to NOPAT
-0.37 221.48 0.46 0.08 0.09 0.06 0.34 0.90 0.04 0.57
Net Debt to NOPAT
6.54 -1,977.54 -7.34 -0.02 -0.13 -0.07 0.34 0.89 0.02 0.45
Long-Term Debt to NOPAT
0.00 80.65 0.00 0.00 0.00 0.00 0.23 0.82 0.00 0.54
Altman Z-Score
5.32 4.97 5.25 5.95 6.21 6.38 6.16 4.87 5.05 5.53
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.78 2.79 3.07 3.02 2.67 2.43 2.34 2.45 2.43 2.38
Quick Ratio
2.53 2.56 2.83 2.82 2.50 2.31 2.25 2.37 2.31 2.32
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
113 97 129 138 156 81 132 13 -79 -167
Operating Cash Flow to CapEx
957.49% 664.59% 2,892.28% 271.99% 419.97% 2,052.88% 2,984.18% 1,274.20% 213.54% 4,824.25%
Free Cash Flow to Firm to Interest Expense
186.20 176.91 227.94 297.98 266.40 120.65 27.04 3.49 -14.81 -47.69
Operating Cash Flow to Interest Expense
39.86 13.58 145.07 13.01 20.60 105.10 24.48 12.70 0.81 40.20
Operating Cash Flow Less CapEx to Interest Expense
35.70 11.54 140.06 8.23 15.70 99.98 23.66 11.70 0.43 39.37
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
2.12 2.22 2.29 2.26 2.48 2.81 2.84 2.87 3.33 4.02
Accounts Receivable Turnover
4.51 4.42 4.33 3.61 3.98 4.37 4.09 4.05 4.94 6.18
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
47.84 52.43 58.48 69.27 85.94 99.69 112.69 132.73 157.96 168.64
Accounts Payable Turnover
0.27 18.25 16.20 12.74 0.10 10.45 9.72 12.79 0.06 14.23
Days Sales Outstanding (DSO)
80.87 82.59 84.25 101.16 91.62 83.43 89.22 90.16 73.92 59.04
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
1,343.44 20.00 22.53 28.65 3,582.05 34.94 37.53 28.54 5,749.99 25.65
Cash Conversion Cycle (CCC)
-1,262.57 62.59 61.72 72.51 -3,490.43 48.49 51.68 61.62 -5,676.07 33.39
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
342 367 374 467 457 462 516 603 604 530
Invested Capital Turnover
3.36 3.49 3.54 3.32 3.81 4.50 4.26 4.45 5.15 6.59
Increase / (Decrease) in Invested Capital
-116 -95 -143 -136 -147 -67 -107 19 120 204
Enterprise Value (EV)
521 397 416 657 786 880 1,055 972 995 1,192
Market Capitalization
598 454 481 658 796 888 1,009 822 991 1,085
Book Value per Share
$12.73 $12.56 $12.63 $13.68 $13.30 $13.12 $13.09 $12.27 $12.11 $11.06
Tangible Book Value per Share
$7.34 $7.18 $7.32 $8.21 $7.90 $7.74 $7.60 $6.72 $6.53 $6.87
Total Capital
423 431 443 472 474 477 517 603 459 560
Total Debt
4.41 6.45 4.10 4.10 6.79 6.91 47 151 7.50 137
Total Long-Term Debt
0.00 2.35 0.00 0.00 0.00 0.00 31 138 0.00 130
Net Debt
-77 -58 -66 -1.14 -10 -7.39 46 151 3.90 107
Capital Expenditures (CapEx)
2.53 1.12 2.85 2.21 2.88 3.43 4.00 3.68 2.02 2.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)
137 156 162 258 250 254 305 396 402 360
Debt-free Net Working Capital (DFNWC)
219 220 232 263 268 269 305 396 406 391
Net Working Capital (NWC)
215 216 228 259 261 262 290 384 398 383
Net Nonoperating Expense (NNE)
1.35 -0.40 2.61 -0.56 0.32 0.53 3.44 2.70 4.31 2.48
Net Nonoperating Obligations (NNO)
-77 -58 -66 -1.14 -10 -7.39 46 151 153 107
Total Depreciation and Amortization (D&A)
4.34 4.50 4.72 4.64 4.47 4.54 4.43 4.90 3.16 3.21
Debt-free, Cash-free Net Working Capital to Revenue
10.22% 10.77% 10.29% 14.51% 12.40% 11.38% 12.55% 14.99% 14.35% 12.78%
Debt-free Net Working Capital to Revenue
16.30% 15.19% 14.71% 14.81% 13.25% 12.02% 12.58% 15.00% 14.47% 13.86%
Net Working Capital to Revenue
15.97% 14.91% 14.45% 14.57% 12.91% 11.71% 11.93% 14.53% 14.21% 13.59%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.13) $0.08 ($0.47) $0.08 $0.28 $0.37 $0.60 $0.82 $1.00 $0.94
Adjusted Weighted Average Basic Shares Outstanding
33.38M 33.02M 33.96M 34.22M 35.16M 34.95M 35.35M 35.86M 37.01M 37.10M
Adjusted Diluted Earnings per Share
($0.13) $0.08 ($0.47) $0.08 $0.28 $0.36 $0.60 $0.81 $0.99 $0.93
Adjusted Weighted Average Diluted Shares Outstanding
33.38M 33.06M 33.96M 34.60M 35.48M 35.15M 35.52M 36.56M 37.54M 37.49M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
32.81M 32.92M 33.81M 34.77M 34.73M 35.15M 35.80M 35.93M 36.82M 37.30M
Normalized Net Operating Profit after Tax (NOPAT)
2.27 2.90 -12 3.26 10.00 14 26 32 41 42
Normalized NOPAT Margin
0.73% 0.92% -3.50% 0.86% 2.41% 3.10% 4.77% 5.21% 6.50% 6.57%
Pre Tax Income Margin
-1.26% 1.08% -5.76% 0.97% 3.13% 4.41% 5.61% 6.44% 6.90% 7.66%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-6.99 5.15 -33.44 8.98 23.00 30.14 7.22 11.87 9.09 14.92
NOPAT to Interest Expense
-3.95 3.91 -23.67 4.61 15.96 19.94 5.09 8.71 7.62 10.66
EBIT Less CapEx to Interest Expense
-11.15 3.11 -38.46 4.20 18.09 25.02 6.40 10.88 8.71 14.09
NOPAT Less CapEx to Interest Expense
-8.12 1.87 -28.69 -0.17 11.06 14.82 4.27 7.71 7.24 9.82
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-256.32% -2,245.67% 500.28% 70.31% 79.38% 60.74% 57.71% 43.00% 18.97% 10.71%

Frequently Asked Questions About Cross Country Healthcare's Financials

When does Cross Country Healthcare's financial year end?

According to the most recent income statement we have on file, Cross Country Healthcare's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Cross Country Healthcare's net income changed over the last 2 years?

Cross Country Healthcare's net income appears to be on a downward trend, with a most recent value of -$14.56 million in 2024, falling from $185.98 million in 2022. The previous period was $72.63 million in 2023. Check out Cross Country Healthcare's forecast to explore projected trends and price targets.

What is Cross Country Healthcare's operating income?
Cross Country Healthcare's total operating income in 2024 was -$16.87 million, based on the following breakdown:
  • Total Gross Profit: $1.32 billion
  • Total Operating Expenses: $1.34 billion
How has Cross Country Healthcare revenue changed over the last 2 years?

Over the last 2 years, Cross Country Healthcare's total revenue changed from $2.80 billion in 2022 to $1.34 billion in 2024, a change of -52.1%.

How much debt does Cross Country Healthcare have?

Cross Country Healthcare's total liabilities were at $170.29 million at the end of 2024, a 20.2% decrease from 2023, and a 65.8% decrease since 2022.

How much cash does Cross Country Healthcare have?

In the past 2 years, Cross Country Healthcare's cash and equivalents has ranged from $3.60 million in 2022 to $81.63 million in 2024, and is currently $81.63 million as of their latest financial filing in 2024.

How has Cross Country Healthcare's book value per share changed over the last 2 years?

Over the last 2 years, Cross Country Healthcare's book value per share changed from 12.11 in 2022 to 12.73 in 2024, a change of 5.1%.



This page (NASDAQ:CCRN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners